Business Context and Reporting Period
Core Scientific, Inc. filed this Form 8-K regarding the January 19, 2022 special meeting of stockholders and the closing of its business combination with Core Scientific Holding Co. The transaction involved Power & Digital Infrastructure Acquisition Corp. (XPDI), XPDI Merger Sub, Inc., and Core Scientific Holding Co. Following the merger, XPDI became Core Scientific, Inc. and was expected to trade on Nasdaq under CORZ and CORZW beginning January 20, 2022.
Key Financial and Capitalization Information
- At the December 7, 2021 record date, XPDI had 34,500,000 outstanding Class A shares and 8,625,000 outstanding Class B shares.
- 26,853,417 shares, or approximately 62.3% of voting shares, were present at the special meeting.
- 12,347,077 Class A shares were redeemed for approximately $10.00 per share, resulting in aggregate redemptions of $123,483,147.34.
- The filing does not provide revenue, profit, cash flow, margin, debt, or post-transaction liquidity figures.
- The approved charter increased authorized capital from 551,000,000 shares, including 550,000,000 common shares and 1,000,000 preferred shares, to 12,000,000,000 shares, including 10,000,000,000 common shares and 2,000,000,000 preferred shares.
Material Changes Versus the Prior Comparable Period
- The business combination was consummated on January 19, 2022, materially changing the company’s corporate structure and business identity.
- The surviving public company adopted the Core Scientific name and planned to list its common stock and warrants under CORZ and CORZW.
- A significant portion of Class A shares was redeemed, reducing the public share base by 12,347,077 shares and removing approximately $123.5 million in redemption proceeds from the trust account.
- Stockholders approved the 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing contains no operating or financial guidance and no management forecast.
- The merger remained subject to the satisfaction or waiver of remaining closing conditions; the filing states that the merger was ultimately consummated.
- The transaction involved substantial share redemptions, which may affect available transaction cash and post-closing ownership; the filing does not provide a clear post-redemption cash balance.
- The adjournment proposal was not presented because sufficient votes were available to approve the other proposals.
- The January 20, 2022 press release was furnished under Regulation FD and was not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Points
- Verify the final post-merger capitalization, including shares outstanding, warrants, equity awards, and ownership percentages.
- Verify the amount of cash remaining after the $123.5 million of redemptions and any transaction expenses or financing activity.
- Review subsequent filings for Core Scientific’s operating results, liquidity, debt obligations, and bitcoin-mining or hosting performance.
- Confirm the effectiveness and terms of the new charter, bylaws, incentive plan, and employee stock purchase plan.
- Review the merger agreement and related disclosures for indemnities, contingencies, conditions, and other transaction-related obligations.